Clinical Trials in IPF Dr Helen Parfrey. Are clinical trials needed ? Essential to determine if a drug therapy is beneficial Identify who will benefit.

Slides:



Advertisements
Similar presentations
Research and Development in Pulmonary Fibrosis: The Future is Bright Glenn D. Rosen, M D Associate Professor of Medicine Interim Co-Chief and Program Director.
Advertisements

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.
IPF MANAGEMENT: WHAT DO WE DO NOW? Steven A. Sahn, MD Professor of Medicine and Director Division of Pulmonary, Critical Care, Allergy and Sleep Medicine.
EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C FOR SEVERE SEPSIS (PROWESS) GORDONR. BERNARD, M.D. et al. The New England Journal of Medicine.
Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of.
The Cystic Fibrosis Therapeutics Development Network and CF Clinical Research at UNM Jennifer L. Taylor-Cousar, MD Assistant Professor, Adult CF Program/Associate.
Criner et al. NEJM 2014: 370; 23 Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) Presented by Ali Naqvi, MD.
Idiopathic Pulmonary Fibrosis Standards of Care & Investigational Therapies Stephen K. Frankel, MD, FCCP Assistant Professor, Interstitial Lung Disease.
IDIOPATHIC PULMONARY FIBROSIS. TREATMENT IN IPF Treatments tried in IPF Antifibrotic Activity Anti-inflammatory Interferon-  1b Pirfenidone Endothelin.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Stages of drug development
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Primary Sclerosing Cholangitis - Clinical Studies - Oslo U. Beuers Academic Medical Center, Univerity of Amsterdam, NL.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
How to Analyze Therapy in the Medical Literature (part 2)
Copyright © 2011 Actelion Pharmaceuticals Ltd SERAPHIN: RESULTS FROM A LANDMARK STUDY.
How to Participate in Research Eric Kleerup, M.D. & Donald Tashkin, M.D. David Geffen School of Medicine at UCLA Los Angeles, California.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
INPULSIS® trial design and baseline characteristics
Adaptive Trial Design Piero Olliaro UNICEF/UNDP/World Bank/WHO Special Programme on Research & Training in Tropical Diseases (TDR) Centre for Tropical.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
OFEV ® (nintedanib) efficacy INPULSIS ® trial results for acute IPF exacerbations Last updated These slides are provided by Boehringer Ingelheim.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
R1 정수웅.  Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs.
Diffuse Parenchymal Lung Disease Diagnostic and Therapeutic Challenges
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Imatinib Treatment for Idiopathic Pulmonary Fibrosis Randomized Placebo-controlled Trial Results Caig E. Daniels; Joseph A. Lasky; Andrew H. Limper Kathleen.
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis N ENGL J MED. May 18, /NEJMoa Talmadge E. King, Jr., M.D.,
Dr Julius Cairn. Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function.
httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.
IPF Disease Management Strategies With an Update on Clinical Trials
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Managing IPF: connecting the dots Pulmonary & Sleep Medicine
Efficacy and Safety of Medicines
Eucrisa™ - Crisaborole
Anastasiia Raievska (Veramed)
IPF Disease Management Strategies: Surveying the Landscape of Therapeutic Options Idiopathic Pulmonary Fibrosis (IPF) Disease Management Strategies: Surveying.
HOPE: Heart Outcomes Prevention Evaluation study
Clinical Trials Medical Interventions
Neal B, et al. Diabetes Care 2015;38:403–411
Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:
Early Clinical Experiences with Nintedanib in 3 Tertiary Interstitial Lung Disease Centres
Filming: 15th of Febuary 2016, London, UK
Clinical Trials.
Real World Experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in Idiopathic Pulmonary Fibrosis (IPF). Nazia Chaudhuri*,
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Nintedanib Dose Modifications
Long-term Data: INPULSIS®-ON
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Baselga J et al. SABCS 2009;Abstract 45.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Interstitial lung disease
Three Steps to Interpret Clinical Trials
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
Corticosteroids in the ICU
Terapia della fibrosi polmonare idiopatica
The FAIR-HF Trial Reference
New Models of Care in Idiopathic Pulmonary Fibrosis
Presentation transcript:

Clinical Trials in IPF Dr Helen Parfrey

Are clinical trials needed ? Essential to determine if a drug therapy is beneficial Identify who will benefit the most from the treatment Side effects associated with the drug therapy Information about the disease

How to determine if a drug treatment is effective? “Controlled” - compare the drug treatment to a placebo “Blinded” - the study co-ordinators and patients do not know what treatment has been given “Endpoints” - markers to indicate if the drug is beneficial IPF trials use lung function tests (FVC), hospital admissions, survival, quality of life, measures of breathlessness “Powered” - sufficient number of patients “Inclusion and exclusion criteria” – how to select patients for a study

Have you taken part in a clinical trial for IPF?

Exciting time for IPF

But, several studies have shown that the treatments have not been effective for IPF Interferon gamma studies (INSPIRE) Bosentan studies (BUILD series) Anti-TNFα studies (Etanercept) Tyrosine kinase inhibitor (Imatinib)

Triple therapy: IFIGENIA study Demedts et al New Engl J Med 2005 Limitations All patients in the study taking prednisolone and azathioprine Not compare treatment with N-acetylcysteine alone with placebo

Interim safety analysis: PANTHER-IPF Phase III trial, double blind placebo controlled to assess effectiveness of NAC Recruited 238 out of 390 patients with mild to moderate IPF Patient enrolment into Pred/Aza/NAC ceased Pred/Aza/NACPlacebo Mortality 11%1% Hospitalisation 29%8% SAE 31%9%

Anticoagulation therapy for IPF Kubo et al, Chest 2005 Limitations Small number of patients Not blinded High drop out in treatment group No exclusion of PE as cause for deterioration

New treatments - Pirfenidone Noble PW et al, Lancet 2011

Cochrane Review of Pirfenidone Studies First licensed treatment for mild to moderate IPF FVC≥50%, TLCO≥35%, 6MWD ≥150m Named patient programme NICE evaluation currently

Clinical Trial Tyrosine kinase inhibitor BIBF 1120 Phase II trial, placebo controlled, 432 patients with IPF Richeldi L et al New Engl J Med 2011

How to find out about clinical trials in IPF? Ask your hospital doctor Clinicaltrials.gov website Details of clinical trials in all areas of medicine Use search function to look for trials related to IPF

Current Clinical Trials in IPF 116 studies in IPF 22 therapeutic trials

On-going clinical trials BIBF 1120 QAX576 Thalidomide Sildenafil Plasma exchange, rituximab and steroids for acute exacerbations Sirolimus Losartan Phase I AB0024 PRM-151 STX-100 CC930 IW001 Clinicaltrials.gov

Summary Importance of clinical trials in evaluating new treatments for IPF Carefully designed Expotential increase in clinical trials for IPF Change how IPF is treated

Thank you for participating in the studies